Eli Lilly has announced a significant Mounjaro price increase in the UK starting 1 September 2025. The rise will affect all private prescriptions, with some doses nearly tripling in cost. While NHS access to Mounjaro remains protected, patients buying privately will see steep price hikes. This decision has been linked not only to Eli Lilly’s global pricing strategy but also to Trump’s drug pricing pressure in the U.S.
Mounjaro Price Hike
- From 1 September 2025, Mounjaro’s private UK prices will rise across all doses.
- The highest dose (15 mg) will increase from £122 to £330.
- Lower doses will also rise significantly; for example, the 5 mg dose nearly doubles.
- NHS patients are unaffected, and pricing remains unchanged under Lilly’s agreement.
- Eli Lilly says the move aligns UK prices with global markets.
- Trump has pressed for higher European drug prices.
Current vs New Prices: Mounjaro Price UK
Prices depend on both the provider and the prescribed dose. Mounjaro is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. As the dose increases, so does the monthly cost.
Mounjaro Dosage (mg) | Current UK Private Price | New UK Price (From Sept 1, 2025) | Increase % |
2.5 mg | £92 | £133 | +45% |
5 mg | £92 | £180 | +96% |
7.5 mg and 10 mg | £107 | £255 | +138% |
12.5 mg and 15 mg | £122 | £330 | +170% |
Note: These are official list prices. Patients buying privately may pay more once pharmacy consultation and dispensing fees are added.
The steepest increases hit patients on the higher doses, where the monthly cost almost triples. Even the starting dose of 2.5 mg will rise by nearly half.
Why Has Eli Lilly Increased the Price of Mounjaro in the UK?
- Global Alignment
When Mounjaro launched in the UK in 2024, prices were set low to speed up NHS access to Mounjaro. Now, Eli Lilly is adjusting prices to align the UK with those in Europe and the U.S.
- U.S. Political Pressure
Trump’s drug pricing pressure has played a role. U.S. leaders argue that American patients should not shoulder higher costs while other countries benefit from cheaper access.
- Rising Demand
Since launch, Mounjaro has become one of the most effective medicines for both type 2 diabetes and weight loss, creating strong global demand.
Who Will Be Affected by the Mounjaro Price Hike?
- Private prescription patients
Anyone paying through online clinics, high street pharmacies, or telehealth providers.
- NHS patients
This is not affected; those receiving weight loss jab Mounjaro UK treatment under the NHS will continue paying only the standard NHS prescription charge.
If you qualify for NHS access to Mounjaro, this is the most cost-effective way to avoid the price hikes.
When Does the Change Take Effect?
The new Mounjaro price UK comes into effect on 1 September 2025. Prescriptions dispensed before this date will remain at current prices. Some private providers are offering bundle deals or “lock-in” prices, but these are temporary.
Will There Be a Mounjaro Shortage in August 2025?
While Eli Lilly has not issued official warnings, pharmacists report that some patients are stockpiling Mounjaro before September to beat the increase. This may cause short-term Mounjaro shortages in August 2025. Pharmacists strongly advise ordering responsibly and only within normal prescribing schedules.
Buying Mounjaro Safely
The sharp price hike may push some patients towards unregulated online sellers. To stay safe:
- Only purchase from GPhC-registered UK pharmacies.
- Check a provider’s licence on the GPhC register.
Cleckheaton Pharmacy provides Mounjaro with in-person pharmacist consultations, ensuring safe prescribing, genuine supply, and personalised support throughout your treatment.
Alternatives to Mounjaro: Wegovy vs Mounjaro UK
With the Mounjaro price hike, many patients are considering alternatives:
- Wegovy (semaglutide)
A similar weekly weight loss injection. Wegovy availability in the UK has improved, but shortages still occur.
- Other treatments
Lifestyle programmes, dietitian support, and NHS weight management services.
When comparing Wegovy vs Mounjaro UK, cost, availability, and individual response to treatment should guide decisions. Speak to your healthcare provider before switching.
Conclusion
From September 2025, private Mounjaro prescriptions in the UK will see sharp price rises, with higher doses nearly tripling in cost. NHS patients remain protected, but private buyers will need to prepare. The Mounjaro price increase UK reflects both global alignment and external political pressures. Patients are encouraged to:
- Explore NHS eligibility.
- Consider alternatives such as Wegovy.
- Only purchase from regulated UK pharmacies.
For advice on safe access to weight loss medicines, visit Cleckheaton Pharmacy or speak directly with one of our pharmacists.
FAQs
From 1 September 2025, private Mounjaro prices in the UK will rise between 45% and 170% depending on the dose. The highest dose will nearly triple in price.
Yes. Many patients may consider switching after the Mounjaro price hike. Wegovy is available in the UK but may also face supply challenges. Always consult your healthcare provider before changing treatment.
The increase aligns UK prices with global markets. Eli Lilly also faced Trump drug pricing pressure, pushing pharmaceutical firms to raise European prices.
Depending on the dose, prices will range from about £133 for 2.5 mg to £330 for 15 mg per month on private prescriptions.
Yes. NHS pricing remains unchanged, and patients will continue paying the standard NHS prescription charge.
Private patients will see steep cost increases, particularly at higher doses. Pharmacies may charge additional consultation and dispensing fees on top of the new list prices.
Alternatives include Wegovy, lifestyle-based NHS programmes, and other medical options. Discuss with your prescriber to see what best suits your needs.
Mounjaro will soon be more expensive than Wegovy in the UK, especially at higher doses. Both drugs are effective, but supply and NHS eligibility differ.
No official timeline has been given. Temporary shortages may occur in August 2025 due to stockpiling, but Eli Lilly has not announced long-term supply issues.
Yes. Clinical trials for an oral tirzepatide are ongoing. If approved, it could offer a tablet alternative in future, though no UK launch date has been confirmed.
